Stryker Forecasts Higher-Than-Expected 2025 Profit on Strong Demand for Surgical Devices

Stryker exceeded Wall Street expectations for its fourth-quarter profit and projected 2025 earnings largely above analyst estimates, driven by robust demand for its medical and surgical devices.

The medical device industry has seen a surge in demand, particularly in the U.S., as more patients—especially older Americans—opt for elective surgeries that were postponed during the COVID-19 pandemic.

2025 Earnings Forecast

Stryker expects its adjusted per-share profit for 2025 to range between $13.45 and $13.70. The midpoint of this range surpasses analysts’ average estimate of $13.51, according to LSEG data.

Spinal Implants Business Sale & Leadership Changes

Separately, Stryker announced plans to sell its U.S. spinal implants business to private investment firm Viscogliosi Brothers, which will form a new company, VB Spine. The deal is expected to close in the first half of 2025.

Additionally, the company named Preston Wells as its new Chief Financial Officer (CFO), effective April 1. Wells, currently finance chief of Stryker’s orthopedics unit, will replace Glenn Boehnlein.

Strong Q4 Sales and Recent Acquisitions
• Medical surgery and neurotechnology unit revenue rose 10.6% to $3.89 billion.
• Orthopedics segment revenue increased 10.8% to $2.55 billion.
• Total Q4 revenue reached $6.44 billion, surpassing analysts’ expectations of $6.36 billion.
• Adjusted earnings per share (EPS) were $4.01, beating estimates of $3.87.

Earlier in January, Stryker announced a $4.9 billion acquisition of Inari Medical, expanding its vascular disease treatment portfolio.

Despite the strong earnings report, Stryker’s shares declined 1.6% to $389 in extended trading.